These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34918591)

  • 1. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi
    Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G
    Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.
    Kay J; Cross RK; Feldman SR; Park Y; Hanauer SB
    Adv Ther; 2024 Feb; 41(2):509-533. PubMed ID: 38110655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S; Chadwick L; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
    Park D; Yun J; Hwang SJ; Park SJ
    Adv Ther; 2019 Feb; 36(2):442-450. PubMed ID: 30554330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
    Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
    Müller-Ladner U; Dignass A; Gaffney K; Jadon D; Matucci-Cerinic M; Lobaton T; Carron P; Gisbert JP; Pande I; Utzinger M; Addison J
    BioDrugs; 2023 Nov; 37(6):873-889. PubMed ID: 37632666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X; Hu R; Peng L; Liu M; Sun Z
    Front Immunol; 2021; 12():638444. PubMed ID: 33889152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
    Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
    Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
    Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.
    Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P
    Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis.
    Di Cesare A; Tronconi G; Fastame TM; Rosi E; Pescitelli L; Ricceri F; Prignano F
    Dermatol Ther; 2020 May; 33(3):e13435. PubMed ID: 32306527
    [No Abstract]   [Full Text] [Related]  

  • 18. PF-06410293: An Adalimumab Biosimilar.
    Lee A; Shirley M
    BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
    Ghil J; Zielińska A; Lee Y
    Curr Med Res Opin; 2019 Mar; 35(3):497-502. PubMed ID: 30561229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS).
    Young D; Harris C; Rahmany S; Iria I; Gonçalves J; Addison J; Harvey J; Latter S; Cummings F
    Int J Clin Pharm; 2024 Oct; 46(5):1091-1101. PubMed ID: 38734866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.